Erin Lavelle
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Erin M.
Lavelle served as the General Manager at Amgen, Inc. from 2017 to 2018.
She was also the Chief Operating Officer at Lundbeck Seattle BioPharmaceuticals, Inc. from 2018 to 2020.
Currently, she is the Executive VP, Chief Operating & Financial Officer at Eliem Therapeutics, Inc. Ms. Lavelle received her undergraduate degree from Yale University in 1998.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 31.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Erin Lavelle
| Unternehmen | Position | Ende |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Director of Finance/CFO | 10.03.2023 |
| ALDER BIOPHARMACEUTICALS, INC. | Chief Operating Officer | 01.02.2020 |
| AMGEN INC. | Corporate Officer/Principal | 01.03.2018 |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
| NEUROGENE INC. | Director/Board Member | - |
Ausbildung von Erin Lavelle
| Yale University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
